Philippe Degive

EPICS is a drug discovery and development company that invents and develops small molecule drugs targeting RNA epigenetic mechanisms involved in cancer development. EPICS’s mission is to utilize its expertise in drug discovery and development to invent novel clinical agents targeting serious unmet medical needs in oncology. We develop products to meet high value-added endpoints. We constantly balance risk and reward in determining if and when to partner our programs.

Newton Biocapital (NBC) is a VC firm focused on early-stage Life Sciences companies targeting chronic health conditions. NBC is among the 8 VC firms certified by AMED in Japan to boost the pharma ecosystem and the only one with offices in Japan/Europe. NBC’s diversified team of experts and its presence in Japan/Europe enable NBC to identify and select the most promising companies based on the outstanding research ecosystem in these two regions. NBC provides investment opportunities that can help patients and society, as well as foster growth of the Japanese/European biotech ecosystems. NBC is a hands-on investor and leverages its expertise to help its portfolio companies focus on the right indication and clinical trial design, thereby helping them progress successfully through the challenging early drug development phases up to the proof of concept in patients. NBC enables time- and cost-effective translation from science to proof of concept in patients that attracts potential acquirers and unlocks value – for patients, companies, and investors. Partner with us to unlock life sciences innovation, grow the biotech sectors and make an impact both locally and internationally.

Novadip Biosciences is a clinical-stage biopharmaceutical company founded to design, develop, and bring to the market a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment. Novadip’s lead allogeneic product, NVD-X3, employs a matrix containing multiple bioactive factors that induce accelerated tissue healing. Designed as an “off-the-shelf” product, NVD-X3 can be shipped and stored at room temperature and offers superior intraoperative handling characteristics. Novadip is also developing NVD-003, an autologous therapy derived from ASCs as a potential single treatment to save limbs and restore mobility in patients with congenital pseudarthrosis of the tibia (CPT). CPT is a rare pediatric bone condition. Learn more about our technology platform and clinical development programs at www.novadip.com Phone number: +32/10 77 92 20 E-mail: info@novadip.com VAT: BE0535.575.602 Privacy policy: https://novadip.com/privacy-policy/

Ncardia is a drug discovery company and expert in human iPSC technology. We operate worldwide with facilities, offices and staff throughout Europe and North America. We work with biopharmaceutical companies in drug discovery worldwide, to leverage the power of stem cell technologies in the development of novel therapies of multiple modalities at any stage of development. Over the past 10 years, we have built the expertise and infrastructure required to differentiate, manufacture and characterize high-quality iPSC-derived cell and disease models. We can facilitate the process of disease modeling and high-throughput screening to accelerate drug discovery. We listen to our customer’s project plans, questions and challenges, and co-develop human iPSC-based solutions that fit their specifications. Explore our website to learn more www.ncardia.com.

About iSTAR Medical iSTAR Medical is committed to delivering breakthrough eye care solutions. Our most advanced product, MINIject, is approved in Europe for the treatment of open-angle glaucoma – the leading cause of irreversible blindness[1] – and we are aiming to seek market approval in the US. We believe MINIject’s unique tissue-integrating capabilities unlock a safer, and more effective option for patients. We are building an exceptional team and pipeline of best-in-class products such as MINIject to establish new treatment paradigms in eye care conditions with the highest patient needs. About MINIject® MINIject is iSTAR Medical’s innovative MIGS device for patients with primary open-angle glaucoma. MINIject combines the unique porous structure of its proprietary STAR material with the power offered by the supraciliary space. As a result, it is designed to enhance natural fluid outflow, reducing intraocular pressure (IOP) and the need for medication, while bio-integrating with surrounding tissue, limiting inflammation, fibrosis and subsequent complications. About Glaucoma Glaucoma is a progressive disease affecting over 100 million people globally, of which primary open-angle glaucoma is the most common form.[1][2] IOP reduction, through medication or surgery, helps delay disease progression.[3] MIGS is the most promising and fastest-growing glaucoma therapy due to its enhanced safety profile.[2] MINIject is potentially best-in-class for its promising long-term efficacy and safety. [1] Jonas JB, Aung T, Bourne RR et al. “Glaucoma”. Lancet 2017; 390: 2083–93 [2] Market Scope, “2021 Glaucoma Surgical Device Market Report”, July 2021. https://www.market-scope.com/pages/reports/267/2021-glaucoma-surgical-device-market-report [3] “European Glaucoma Society Terminology and Guidelines for Glaucoma”, 4th Edition: British Journal of Ophthalmology. 2017;101:1-195 https://bjo.bmj.com/content/101/5/73 MINIject is a registered trademark in the European Union.

Ogeda SA is a pharmaceuticals company based out of Route de Lennik 802, Brussels, Belgium.

CAPRICORN HEALTH-TECH FUND is a company based out of 19 Lei, Leuven, Belgium.

Cell Signaling Technology for Organ Repair and Regeneration We care for liver Our advanced therapy aims to restore liver function thanks to immunomodulatory and regenerative properties of Hepastem

ORSA (ex-Investsud) est un fonds d’investissement spécialisé dans le financement et l’accompagnement des PME wallonnes. Nous investissons entre 500 000 € et 2 500 000 € en capital et quasi-capital pour soutenir les projets d’innovation, de développement, de croissance et de transmission. Au-delà du financement, nous apportons un accompagnement stratégique de long terme. Depuis plus de 40 ans, nous mettons notre expertise financière et notre expérience du terrain au service des entrepreneurs, en nous impliquant à leurs côtés pour les aider à franchir les étapes décisives de leur développement. Doté de plus de 120 millions d’euros de moyens d’action, ORSA est un fond evergreen, ce qui lui permet d’intervenir avec un horizon de long terme, sans contrainte de sortie, afin de construire une valeur durable aux côtés des dirigeants. Nos investissements s’articulent autour de deux thématiques : – Industrie : production, équipement et construction – Innovation : santé, digital et durabilité Notre gouvernance associe capitaux privés et publics, portée majoritairement par des entrepreneurs wallons. Cette structure nous permet de conjuguer stabilité financière, vision entrepreneuriale et ancrage territorial. Oser ensemble. Nous sommes présents à chaque étape de la vie de votre entreprise pour : – Financer le développement de votre PME : Accélérez votre croissance sans compromettre votre indépendance. – Sécuriser et préparer l’avenir de votre PME : Préparez l’avenir de votre entreprise avec un associé durable. – Reprendre une PME : Concrétisez votre acquisition avec un accompagnement stratégique et financier. – Financer votre projet biotech : Développez votre innovation avec un associé qui comprend vos enjeux scientifiques. – Accélérer votre start-up / scale-up : Franchissez vos prochaines étapes de croissance avec un investisseur engagé.

EPICS is a drug discovery and development company that invents and develops small molecule drugs targeting RNA epigenetic mechanisms involved in cancer development. EPICS’s mission is to utilize its expertise in drug discovery and development to invent novel clinical agents targeting serious unmet medical needs in oncology. We develop products to meet high value-added endpoints. We constantly balance risk and reward in determining if and when to partner our programs.